Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Participants on weekly injections of 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, and 45.3% of participants achieved ≥ 30% weight loss.

Analysis of data from the PUSH randomized trial affirmed that more fluid increase is better, but some still helps.

Biopsy and next-generation sequencing identified an HSV 1 variant causing ulcerative esophagitis and ileitis in a healthy 26 ...

A new study finds that prior authorization requirements vary widely across major insurers and suggests large language models ...

Health leaders in Spain debate balancing maternal-fetal safety with respectful, informed care, spotlighting birth plans, ...

Experts say biomarker research and multiomics are pushing rheumatology toward more individualized treatment strategies and earlier disease classification.

An analysis conducted in an integrated healthcare system provided insights into the long-term healthcare burden of cCMV ...

Nutrition science is closing in on truly personalized dietary advice. The bigger challenge? Making sure it does not only land ...

Physician-focused agents have helped doctors navigate job offers, professional growth, media opportunities, and more. Do you ...

Creatinine muscle index can serve as a blood biomarker to estimate low muscle mass and identify individuals at an increased ...

The FDA’s recent approval of baxdrostat may usher in new possibilities for treatment for uncontrolled hypertension.